68Ga-FAPI PET/CT 作为 18F-FDG PET/CT 的替代方法用于浸润性小叶乳腺癌显像
本回顾性分析纳入 23 例原发性浸润性小叶癌女性患者,均接受 18F-FDG PET/CT 与 68Ga-FAPI PET/CT 检查,两次扫描间隔 1 周且期间未行治疗。68Ga-FAPI PET/CT 在原发灶、腋窝淋巴结及远处转移检出上优于 18F-FDG PET/CT,肿瘤摄取及靶本比更高。作者认为 68Ga-FAPI PET/CT 可补充 18F-FDG PET/CT,并有望作为未来研究中的替代显像方法。
要点
- 68Ga-FAPI PET/CT 肿瘤摄取及靶本比高于 18F-FDG PET/CT(P < 0.001)。
- 68Ga-FAPI PET/CT 原发灶摄取显著增高(P < 0.001),并检出多灶性癌等额外病灶。
- 68Ga-FAPI PET/CT 检出更多腋窝淋巴结转移且摄取更高(P = 0.012),并检出更多骨、肝转移灶。
核心结论
- 68Ga-FAPI PET/CT 在浸润性小叶癌显像中优于 18F-FDG PET/CT。
- 68Ga-FAPI PET/CT 在原发乳腺肿块、腋窝淋巴结和远处转移检出方面表现突出,可补充 18F-FDG PET/CT,并有望作为未来研究中的替代显像方法。
研究设计与样本
- 回顾性分析,纳入 23 例原发性浸润性小叶癌女性患者(平均年龄 51 岁),肿瘤为激素受体阳性、人表皮生长因子受体 2 阴性。
- 患者均接受 18F-FDG PET/CT 与 68Ga-FAPI PET/CT 检查,两次扫描间隔 1 周,期间未行任何治疗。
- 两种显像方法在所有病灶部位与所用参考标准进行比较,病灶视觉分类,示踪剂活性采用 SUVmax、肿瘤与背景摄取比及摄取比分析。
- 统计分析使用 SPSS 22.0,以 P 值小于 0.05 为统计学显著。
主要发现
- 68Ga-FAPI PET/CT 较 18F-FDG PET/CT 肿瘤活性及肿瘤与背景摄取比更高(P < 0.001)。
- 68Ga-FAPI PET/CT 原发肿瘤摄取显著增高(P < 0.001),并检出额外病灶,包括多灶性癌。
- 68Ga-FAPI PET/CT 腋窝淋巴结转移检出更频繁且摄取值更高(P = 0.012)。
- 68Ga-FAPI PET/CT 检出更多病灶,包括骨和肝转移。
- 病理特征与显像方法无显著相关,但瘤周淋巴细胞比值与 68Ga-FAPI PET/CT 对 18F-FDG PET/CT 的摄取比呈正相关(P = 0.026)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accurate staging of invasive lobular carcinoma (ILC), a subtype of breast cancer, is vital for effective clinical management. Although 18F-FDG PET/CT is a commonly used tool, its efficacy varies across different histologic subtypes. To mitigate this challenge, our investigation delves into the potential utility of 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT as an alternative for staging ILC, aiming to address a significant research gap using a more expansive patient cohort than the smaller samples commonly found in the existing literature. Methods: In this retrospective analysis, women diagnosed with primary ILC of the breast underwent both 18F-FDG PET/CT and 68Ga-FAPI PET/CT. Both modalities were compared across all lesion locations with the used reference standard. The interval between scans was 1 wk, without any intervening treatments. Lesions were categorized visually, and tracer activity was analyzed using SUVmax, tumor-to-background uptake ratio, and uptake ratios. Both modalities were compared across various parameters, and statistical analysis was performed using SPSS 22.0. A P value of less than 0.05 was chosen to determine statistical significance. Results: The study included 23 female ILC patients (mean age, 51 y) with hormone-positive, human epidermal growth factor receptor type 2-negative tumors. Most (65%) had the luminal A subtype. 68Ga-FAPI PET/CT outperformed 18F-FDG PET/CT, with higher tumoral activity and tumor-to-background uptake ratios (P < 0.001). Primary tumors showed significantly increased uptake with 68Ga-FAPI PET/CT (P < 0.001), detecting additional foci, including multicentric cancer. Axillary lymph node metastases were more frequent and had higher uptake values with 68Ga-FAPI PET/CT (P = 0.012). Moreover, 68Ga-FAPI PET/CT identified more lesions, including bone and liver metastases. Pathologic features did not significantly correlate with imaging modalities, but a positive correlation was observed between peritumoral lymphocyte ratio and 68Ga-FAPI PET/CT-to-18F-FDG PET/CT uptake ratios (P = 0.026). Conclusion: This study underscores 68Ga-FAPI PET/CT's superiority over 18F-FDG PET/CT for ILC. 68Ga-FAPI PET/CT excels in detecting primary breast masses, axillary lymph nodes, and distant metastases; can complement 18F-FDG PET/CT in ILC; and holds potential as an alternative imaging method in future studies.
引用
- Sahin E, Kus T, Aytekin A, et al. 68Ga-FAPI PET/CT as an Alternative to 18F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma. J Nucl Med. 2024. PMID: 38485276. doi:10.2967/jnumed.123.266798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。